In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.
| Pharmaceuticals Industry | Healthcare Sector | Robert B. Ford CEO | XMIL Exchange | US0028241000 ISIN |
| US Country | 114,000 Employees | 15 Oct 2025 Last Dividend | 2 Jan 2013 Last Split | 13 Jan 1978 IPO Date |
Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.
Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains: